WebMar 1, 2024 · During preclinical development, daratumumab was specifically selected for its ability to mediate complement-dependent cytotoxicity (CDC). 9 It is has also been shown to kill target cells via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and FCγR-mediated cross-linking–induced apoptosis. 6 … WebOct 27, 2024 · Daratumumab side effects. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or …
Daratumumab: a first-in-class CD38 monoclonal antibody for the ...
WebJan 27, 2024 · Treatment of multiple myeloma patients with daratumumab, a novel anti‐CD38 MoAb, resulted in false‐positive indirect antiglobulin tests (IATs) for all patients for 2 to 6 months after infusion, which precluded the correct identification of irregular blood group antibodies for patients requiring blood transfusion. 124 WebMar 23, 2024 · The primary endpoint is the significant reduction of serum anti-dsDNA antibody titers after 8 repeated weekly injections of daratumumab at Week 12, i.e. 4 weeks after the last daratumumab injection, compared to baseline Secondary Outcome Measures : reaching home program good shepherd
Daratumumab - Chemotherapy Drug Information - Chemocare
WebDARAZLEX® (daratumumab) is a human monoclonal IgG κ antibody targeting CD38 that has been shown to provide clinical benefit as monotherapy in heavily pre-treated multiple … WebMar 7, 2024 · Daratumumab injection (generic name: daratumumab) was approved by Food and Drug Administration (FDA) in the United States in 2015 and China in 2024 for the treatment of recurrent or refractory multiple myeloma (RRMM). WebJan 10, 2024 · Positive for hepatitis B virus (HBsAg or HBcAb-positive) antibodies, hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV), or treponema pallidum antibodies (Anti-TP); History of drug abuse or substance abuse, or positive in urine drug screening; reaching home program canada